Groenemeijer, B E <br/><br/>
Genetic variant showing a positive interaction with beta-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients. The Ser447-stop substitution in the lipoprotein lipase gene. REGRESS Study Group.  [electronic resource] 

 -  Circulation  Jun 1997 
 - 2628-35 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0009-7322 
<br/><br/><label>Standard No.: </label>10.1161/01.cir.95.12.2628  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adrenergic beta-Antagonists--therapeutic use<br/>Alleles<br/>Cholesterol, HDL--blood<br/>Coronary Artery Disease--blood<br/>Enzyme Inhibitors--therapeutic use<br/>Gene Frequency<br/>Genetic Variation<br/>Genotype<br/>Humans<br/>Hydroxymethylglutaryl CoA Reductases<br/>Lipoprotein Lipase--blood<br/>Male<br/>Middle Aged<br/>Mutation<br/>Pravastatin--therapeutic use<br/>Triglycerides--blood